Future studies could explore the efficacy of gene therapy or small-molecule agonists designed to upregulate or mimic ZFP36 activity in adipose tissue, testing whether such interventions can reverse or prevent obesity and insulin resistance in preclinical models. The gene discussed is ZFP36; the disease is obesity due to melanocortin 4 receptor deficiency.